Risk-factors for re-admission and outcome of patients hospitalized with confirmed COVID-19.
Hefziba GreenDafna YahavNoa Eliakim-RazNitzan Karny-EpsteinShiri KushnirTzippy ShochatBoaz TadmorAlon GrossmanPublished in: Scientific reports (2021)
Burden of COVID-19 on Hospitals across the globe is enormous and has clinical and economic implications. In this retrospective study including consecutive adult patients with confirmed SARS-CoV-2 who were admitted between 3/2020 and 30/9/20, we aimed to identify post-discharge outcomes and risk factors for re-admission among COVID-19 hospitalized patients. Mortality and re-admissions were documented for a median post discharge follow up of 59 days (interquartile range 28,161). Univariate and multivariate analyses of risk factors for re-admission were performed. Overall, 618 hospitalized COVID-19 patients were included. Of the 544 patient who were discharged, 10 patients (1.83%) died following discharge and 50 patients (9.2%) were re-admitted. Median time to re-admission was 7 days (interquartile range 3, 24). Oxygen saturation or treatment prior to discharge were not associated with re-admissions. Risk factors for re-admission in multivariate analysis included solid organ transplantation (hazard ratio [HR] 3.37, 95% confidence interval [CI] 2.73-7.5, p = 0.0028) and higher Charlson comorbidity index (HR 1.34, 95% CI 1.23-1.46, p < 0.0001). Mean age of post discharge mortality cases was 85.0 (SD 9.98), 80% of them had cognitive decline or needed help in ADL at baseline. In conclusion, re-admission rates of hospitalized COVID-19 are fairly moderate. Predictors of re-admission are non-modifiable, including baseline comorbidities, rather than COVID-19 severity or treatment.
Keyphrases
- sars cov
- coronavirus disease
- emergency department
- end stage renal disease
- cognitive decline
- chronic kidney disease
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- respiratory syndrome coronavirus
- stem cells
- cardiovascular disease
- cardiovascular events
- coronary artery disease
- mild cognitive impairment
- patient reported
- case report
- cell therapy
- adipose tissue
- data analysis
- combination therapy